BioMarin Pharmaceutical | BMRN - Przychody Ze Sprzedaży





Obroty Zmiana Data
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amgen USD 9.9B 340M 2025-12
Bayer EUR 11.44B 1.78B 2025-12
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 875M 99M 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Incyte USD 1.27B 240M 2026-03
Insmed USD 263.8M 121.8M 2025-12
Ionis Pharmaceuticals USD 246M 43M 2026-03
Moderna USD 678M 342M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 12.14B 65M 2026-03
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12